Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease

Abstract

Anti-IL-17 medications are associated with IBD exacerbation. Caution should be used in prescribing these medications in patients with diagnosed IBD or personal history suggestive of IBD.

Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis

“…Four patients on adalimumab developed severe conjunctivitis, miliary tuberculosis, neuroborreliosis, and herpes virus encephalitis, respectively, and five patients experienced paradoxal worsening and exanthematous outbreak of psoriasis. There are reports showing concerns during treatment with IL‐17 class of inhibitors regarding the occurrence of inflammatory bowel disease (IBD) . In our registry, one case of newly diagnosed and endoscopically confirmed Crohn's disease was reported during the treatment with secukinumab.…”

Use of Nonsteroidal Anti-Inflammatory Drugs and Biological Agents for the Treatment of Axial Spondyloarthritides. Recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization «the Association of Rheumatology of Russia»

“…Этанерцепт способен вы-звать ухудшение течения/активацию ВЗК [2,7,14,49]. Следует соблюдать осторожность при назначении препа-рата секукинумаб пациентам с обострением болезни Кро-на, поскольку в клинических исследованиях наблюдалось усугубление течения болезни Крона, в некоторых случаях тяжелое [63,64].…”

“…Наличие ВЗК у больных АС допускает лечение с использованием только моноклональных антител к ФНОa, I A назначение таким пациентам этанерцепта и иИЛ17А не показано [7,13,49,63,64] 2. Скрининг на наличие активной или латентной туберкулезной инфекции обязателен перед назначением I A любого ГИБП [65,66] 3.…”

Severe colitis complicating secukinumab (Cosentyx ® ) therapy

“…In a systematic review, the incidence of CD and UC in secukinumab‐treated patients was 110 and 150 per 100 000 patient‐years respectively . This represents a > 10‐fold increase in incidence compared with the background risk of 0.5–10.6 and 0.9–24.3 per 100 000 patient years .…”

“…IL‐17‐mediated induction of T‐helper (Th)17 lymphocytes is known to be important in triggering IBD, and inhibition of this pathway was expected to treat IBD. A trial of secukinumab for IBD unexpectedly showed worse outcomes in the active treatment arm . In the pivotal AS secukinumab trials, five patients treated with secukinumab developed either de novo colitis or exacerbations of existing colitis …”